Meeting
2019 Genitourinary Cancers Symposium
Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Susan Halabi
Duke University Medical Center, Durham, NC
Susan Halabi , Sandipan Dutta , Kim N. Chi , Catherine M. Tangen , Daniel Peter Petrylak , John C. Araujo , Karim Fizazi , David I. Quinn , Celestia S. Higano , Ian Tannock , Eric Jay Small , William Kevin Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT00004001
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 186)
DOI
10.1200/JCO.2019.37.7_suppl.186
Abstract #
186
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
First Author: Gregory Russell Pond
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb
Poster
2020 Genitourinary Cancers Symposium
Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921.
First Author: Daniel Peter Petrylak
Poster
2020 Genitourinary Cancers Symposium
Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data.
First Author: Anish B. Parikh